Author:
Rizos E.N.,Chatziioannou S.,Douzenis A.,Siafakas N.,Katsantoni E.,Nikolaidou P.,Papathanasiou M.,Lykouras L.
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology
Reference24 articles.
1. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population;Brar;An. Clin. Psychiatr.,2008
2. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha1-adrenergic receptors in vitro;Bymaster;Schizophr. Res.,1999
3. Atypical antipsychotics, tardive dyskinesia, and D2 receptors;Duggal;Am. J. Psychiatr.,2006
4. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia;Emsley;J. Clin. Psychiatr.,2004
5. D2 and 5-HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study;Gefvert;Eur. Neuropsychopharmacol.,2001
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献